Compare Moderna, Inc. (MRNA) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Ferrari NV — how do they compare? Moderna, Inc. trades at $206.35 (market cap $78.65B), while Ferrari NV trades at $387.94 (market cap $67.35B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Ferrari NV pays a 1.09% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Ferrari NV for 126 Days on average.
| MRNA | RACE | |
|---|---|---|
Market Cap | $78.65B | $67.35B |
Volume | 37,373,437 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $436.54 |
52-Week Low | $22.36 | $314.63 |
Typical Hold Time | 59 Days | 126 Days |
Enterprise Value | $74.80B | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Ferrari (RACE) trades at $390.13, up 0.97% today, with a bearish technical signal but strong fundamentals including 22.25% net income margin and consistent earnings beats. Revenue grew to $7.15B in 2025, and the company is executing a share buyback program. Analyst consensus is bullish with a $462.75 price target, though technical indicators show resistance near $390.
The stock offers upside based on premium brand strength and profitability, but faces risks from high valuation multiples (P/E 37.19) and economic sensitivity. Institutional accumulation and positive media coverage support sentiment, yet investors should weigh technical resistance against fundamental growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
